Novartis Withdraws Marketing Application for Ruvise

Published: Thursday, January 24th 2013

(Reuters) - Swiss drugmaker Novartis has withdrawn a marketing application for its drug Ruvise, designed to treat arterial hypertension, the European Medicines Agency (EMA) said on Thursday.

Read more.

Comment(s)

Your comments are valuable to us. Thank you.

Arena Withdrawing Obesity Drug Regulatory Application in Europe

Novartis Under U.S. Investigation for Tekturna Marketing

Blame Sandy, 12/3/12

Vivus Is in Talks With Potential Marketing Partners

Teva to Market Alexza Agitation Treatment in the U.S.